RET and neoplasm: SY-5007 demonstrated significant anti-tumor efficacy in both patients with detectable and undetectable RET variations at baseline, achieving an ORR of 57.4% (35/61, 95% CI 44.1–70.0%) and 60.4% (32/53, 95% CI 46.0-73.5%), respectively, along with a median PFS of 13.8 months (95% CI 10.0–15.5) and NE (p = 0.0011, Supplementary Fig. 5a and Supplementary Table 6).